@entity1822 ( @entity1822 ) constitute approximately one quarter of all @entity242 and are usually defined by morphologic criteria and/or immunoreactivity for actin or @entity2283 . Among high-grade lesions, the distinction from undifferentiated @entity242 (UPS) can be problematic, and previous studies have shown that a significant number of @entity11293 cases may be hiding under the diagnosis of UPS. We recently described 3 novel molecular @entity11293 subtypes that are distributed similarly over @entity1822 of gyneocologic and non-gyneocologic origins. The group 1 subtype shows an improved disease-specific survival compared with the other 2 groups that is independent of histologic grade. Group 1 comprises approximately 25% of all @entity1822 , and is defined by a shared pattern of gene expression, a distinct pattern of genomic changes, and reactivity for at least 3 of 5 immunohistochemistry (IHC) markers (smooth muscle gamma actin, @entity25045 , @entity1 muscle cofilin2, @entity19077 , and sarcolemmal membrane associated protein), as tested on 271 cases of @entity11293 in tissue microarrays. These IHC markers have not been well characterized in @entity11293 . Here we provide a characterization of these 5 markers across normal tissues, an additional 59 cases of @entity11293 , and a wide range of 565 non- @entity11293 soft tissue @entity5 from 44 diagnostic categories, with a focus on UPS. When analyzed individually, the 5 markers were found to be expressed in many @entity242 other than @entity1822 . However, when analyzed by the same criteria used for the recognition of group 1 @entity1822 , in which a case is scored positive when at least 3 of 5 markers reacted, coordinate expression was seen in significant numbers of cases from only 3 diagnostic groups that included 22% of @entity2909 (n=22), 16% of @entity674 (n=43), and 18% of @entity6019 (n=11). In addition, 5% (n=57) of UPSs showed a staining pattern similar to that seen in group 1 @entity1822 . To further examine the possibility that group 1 @entity11293 constitutes a small part of cases diagnosed as UPS, we examined the expression of the top 500 genes from the group 1 @entity11293 expression signature in 29 UPSs by complementary DNA microarray. Unsupervised hierarchical clustering of 29 UPS expression showed that 2 (7%) had coordinated high levels of expression of genes from the group 1 @entity11293 signature, a rate similar to that seen by IHC analysis. These findings show that group 1 @entity11293 IHC markers smooth muscle gamma actin, @entity25045 , @entity1 muscle cofilin2, @entity19077 , and sarcolemmal membrane associated protein when coordinately expressed have specificity for a subset of @entity11293 when compared with other @entity242 , and may be useful for the recognition of group 1 @entity11293 cases within cases diagnosed as UPS.

Expression of subtype-specific group 1 XXXX markers in a wide variety of @entity242 by gene expression analysis and immunohistochemistry.

@entity1 :: ('9606', 'Species') :: ['human'] @entity25045 :: ('845', 'Gene') :: ['calsequestrin 2'] @entity2283 :: ('1674', 'Gene') :: ['desmin'] @entity19077 :: ('4638', 'Gene') :: ['myosin light chain kinase'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas', 'pleomorphic sarcoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity11293 :: ('MESH:C535903', 'Disease') :: ['LMS', 'non-LMS sarcomas'] @entity6019 :: ('MESH:D018203', 'Disease') :: ['endometrial stromal sarcomas'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['LMSs', 'Leiomyosarcomas'] @entity674 :: ('MESH:D046152', 'Disease') :: ['gastrointestinal stromal tumors'] @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyomas']
@entity1822 :: (MESH:D007890,Disease) :: ['leiomyosarcoma']
